2026 ICD-10-CM Diagnosis Code Q93.51Angelman syndrome

ICD-10-CM Codes›Q00-Q99›Q90-Q99›Q93

ICD-10-CM Q93.51
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Q93.51 is a billable ICD-10-CM diagnosis code for angelman syndrome. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Chromosomal abnormalities.

Code Identity

ICD-10-CM Code
Q93.51
Billable Status
Yes — Valid for Submission
Code Describes
Angelman syndrome
Short Description
Angelman syndrome
Same as the full description in the CMS dataset.
Parent Code
Q93.5
Other deletions of part of a chromosome

Code Classification

ChapterQ00-Q99Congenital malformations, deformations and chromosomal abnormalities
SectionQ90-Q99Chromosomal abnormalities, not elsewhere classified
CategoryQ93Monosomies and deletions from the autosomes, not elsewhere classified
This CodeQ93.51Angelman syndrome

Present on Admission (POA)Billing

Q93.51 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Angelman syndrome
  • Angelman syndrome due to maternal monosomy 15q11q13

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Angelman syndrome
    • Happy puppet syndrome
    • Syndrome
      • Angelman
    • Syndrome
      • happy puppet

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR MAL009
Chromosomal abnormalities
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Angelman Syndrome

    a syndrome characterized by multiple abnormalities, mental retardation, and movement disorders. present usually are skull and other abnormalities, frequent infantile spasms (spasms, infantile); easily provoked and prolonged paroxysms of laughter (hence happy); jerky puppetlike movements (hence puppet); continuous tongue protrusion; motor retardation; ataxia; muscle hypotonia; and a peculiar facies. it is associated with maternal deletions of chromosome 15q11-13 and other genetic abnormalities. (from am j med genet 1998 dec 4;80(4):385-90; hum mol genet 1999 jan;8(1):129-35)

  • Angelman Syndrome

    a genetic syndrome characterized by mental retardation, speech impairment, microcephaly, ataxia, and seizures. the majority of cases result from deletions on the long arm of chromosome 15. a minority of cases result from mutations in the ube3a gene.

  • NIPA1 Gene|NIPA1|NIPA1|Non Imprinted In Prader-Willi/Angelman Syndrome 1 Gene

    this gene may be involved in the development of the nervous system.

  • NIPA1 wt Allele|FSP3|MGC102724|MGC35570|Non Imprinted In Prader-Willi/Angelman Syndrome 1 wt Allele|SPG6|Spastic Paraplegia 6 (Autosomal Dominant) Gene

    human nipa1 wild-type allele is located in the vicinity of 15q11.2 and is approximately 43 kb in length. this allele, which encodes non-imprinted in prader-willi/angelman syndrome region protein 1, may play a role in nervous system development. mutations in the gene are associated with autosomal dominant spastic paraplegia 6.

  • NIPA2 Gene|NIPA2|NIPA2|Non Imprinted In Prader-Willi/Angelman Syndrome 2 Gene

    this gene may play a role in prostate cancer.

  • NIPA2 wt Allele|MGC5466|Non Imprinted In Prader-Willi/Angelman Syndrome 2 wt Allele

    human nipa2 wild-type allele is located in the vicinity of 15q11.2 and is approximately 29 kb in length. this allele, which encodes non-imprinted in prader-willi/angelman syndrome region protein 2, may be involved in prostate cancer.

  • Non-Imprinted In Prader-Willi/Angelman Syndrome Region Protein 1

    non-imprinted in prader-willi/angelman syndrome region protein 1 (329 aa, ~35 kda) is encoded by the human nipa1 gene. this protein may be involved in the development of the nervous system.

  • Non-Imprinted In Prader-Willi/Angelman Syndrome Region Protein 2

    non-imprinted in prader-willi/angelman syndrome region protein 2 (360 aa, ~39 kda) is encoded by the human nipa2 gene. this protein may play a role in prostate cancer.

  • UBE3A Gene|UBE3A|UBE3A|Ubiquitin Protein Ligase E3A (Human Papilloma Virus E6-Associated Protein, Angelman Syndrome) Gene

    this gene is involved in protein turnover.

  • UBE3A wt Allele|ANCR|AS|E6-AP|E6AP|EPVE6AP|FLJ26981|HPVE6A|Ubiquitin Protein Ligase E3A (Human Papilloma Virus E6-Associated Protein, Angelman Syndrome) wt Allele

    human ube3a wild-type allele is located within 15q11-q13 and is approximately 102 kb in length. this allele, which encodes ubiquitin-protein ligase e3a, plays a role in protein turnover by targeting substrate proteins for degradation. mutations in this gene are associated with angelman syndrome.

  • Magnesium Transporter NIPA1|NIPA1|Non-Imprinted In Prader-Willi/Angelman Syndrome Region Protein 1|Spastic Paraplegia 6 Protein

    magnesium transporter nipa1 (329 aa, ~35 kda) is encoded by the human nipa1 gene. this protein may be involved in the development of the nervous system.

  • Magnesium Transporter NIPA2|NIPA2|Non-Imprinted In Prader-Willi/Angelman Syndrome Region Protein 2

    magnesium transporter nipa2 (360 aa, ~39 kda) is encoded by the human nipa2 gene. this protein may play a role in prostate cancer.

  • NIPA1 wt Allele|FSP3|MGC102724|MGC35570|NIPA Magnesium Transporter 1 wt Allele|Non Imprinted In Prader-Willi/Angelman Syndrome 1 Gene|Nonimprinted Gene In Prader-Willi Syndrome/Angelman Syndrome Chromosome Region 1 Gene|SLC57A1|SPG6|Spastic Paraplegia 6 (Autosomal Dominant) Gene

    human nipa1 wild-type allele is located in the vicinity of 15q11.2 and is approximately 43 kb in length. this allele, which encodes non-imprinted in magnesium transporter nipa1 protein, may play a role in nervous system development. mutations in the gene are associated with autosomal dominant spastic paraplegia 6.

  • NIPA2 wt Allele|MGC5466|NIPA Magnesium Transporter 2 wt Allele|Non Imprinted In Prader-Willi/Angelman Syndrome 2 Gene|Nonimprinted Gene In Prader-Willi Syndrome/Angelman Syndrome Chromosome Region 2 Gene|SLC57A2

    human nipa2 wild-type allele is located in the vicinity of 15q11.2 and is approximately 29 kb in length. this allele, which encodes magnesium transporter nipa2 protein, may be involved in prostate cancer.

Patient EducationClinical

Developmental Disabilities

Developmental disabilities are conditions that are usually present at birth. They can affect a child's growth and development. These conditions can cause physical, learning, language, or behavior issues. They can include:

The full article covers:

  • What are developmental disabilities?
  • What causes developmental disabilities?
  • How are developmental disabilities diagnosed?
  • What are the treatments for developmental disabilities?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Code History & ChangesHistory

Replacement Q93.51 replaces the following previously assigned code(s):

  • Q93.5 - Other deletions of part of a chromosome
FY 2019AddedAdded to the ICD-10-CM code setEffective October 1, 2018.
FY 2020–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Q93.51Overview

Is Q93.51 (Other deletions of part of a chromosome) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report angelman syndrome on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is Q93.51 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for angelman syndrome on inpatient claims.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.